<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=192888919167017&amp;ev=PageView&amp;noscript=1">
Tuesday,  May 28 , 2024

Linkedin Pinterest
News / Business / Business Briefs

CytoDyn continues COVID-19 treatment test

The Columbian
Published: March 27, 2020, 3:26pm

Vancouver-based biotechnology company CytoDyn announced Friday that it has now enrolled seven patients in a test to see if the company’s flagship treatment product can be used to effectively treat COVID-19.

The treatment is an antibody called leronlimab, originally created to treat HIV, but CytoDyn theorized that it could also function as an anti-inflammatory agent that could prevent COVID-19 patients from developing Acute Respiratory Distress Syndrome, a potentially lethal complication of COVID-19.

CytoDyn received permission from the Food and Drug Administration to fast-track a test, and it announced Friday that it has begun to receive results from the first four patients, all of whom are at a medical facility in New York.

The company also announced on Friday that it submitted another refinement to its proposal to the FDA for a broader clinical trial that would test 75 patients for up to six weeks.